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The best therapeutic strategy in virus-induced vasculitides should take into account the etiology of the
disease and be adapted to the pathogenesis. The combination of antiviral treatments and plasma
exchanges has been proven effective in polyarteritis nodosa (PAN). In human immunodeﬁciency virus
(HIV)-related vasculitis this strategy is also effective and does not jeopardize, like cytotoxic agents, the
outcome of AIDS. In vasculitis related to HCV-associated cryoglobulinemia, plasma exchanges
improve the outcome but the poor effectiveness of antiviral drugs is not able to favor, usually, a deﬁnite
recovery of the patients and relapses are frequent.
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INTRODUCTION
Viruses have been demonstrated to be the cause of several
vasculitides. Two major vasculitides are the consequence
of viral infection: hepatitis B virus (HBV) is responsible
for classic polyarteritis nodosa (PAN) (Guillevin et al.,
1995) and hepatitis C virus (HCV) for mixed cryoglobu-
linemia (Ferri et al., 2003). Other viruses can also be
associated, albeit less frequently, to the occurrence of
vasculitis, like human immunodeﬁciency virus (HIV)
(Gherardi et al., 1993), parvovirus B19 among others. The
demonstration of a close relationship between viral
infection and vasculitis has justifed a new therapeutic
approach, avoiding prolonged administration of steroids
and cytotoxic agents and based on the combination of
antiviral agents and plasma exchange (PE). Herein, we
focus on the management of virus-associated vasculitides.
POLYARTERITIS NODOSA
A close relationship has been demonstrated between PAN
and HBV infection (Tre ´po, 1972). Infections due to
contaminated blood transfusions have now disappeared in
developed countries, because of blood testing and donor
selection, but that intravenous drug use is becoming the
major cause of HBV-related PAN (Guillevin et al., 1995).
The development of vaccines against HBV and their
administration to people at risk also explain the dramatic
decrease of the number of new cases observed since 1989.
During the 1970s, the prevalence of HBV infection in
patients with classic PAN reached 50%. For the last 2
years, fewer than 10 patients a year have been identiﬁed
throughout France (Guillevin et al., 2004).
Some other viruses have been associated with the
occurrenceofPANbutcouldonlyexplaintheoccurrenceof
a few cases per year. HCV does not seem to be a major
etiological factor for PAN despite some descriptions
(Cacoub et al., 1992). GB virus-C, when sought in patients
withPAN,hasnotbeenfoundtobeanagentresponsiblefor
the disease (Servant et al., 1998). When present, HCV was
oftenobservedinassociationwithotherviruses.Anecdotal
parvovirus B19 infections have been described but
a systematic survey of patients with PAN did not show a
higher prevalence of parvovirus B19 in patients than the
control population (Leruez et al., 1994; Eden et al., 2002).
The immunological process responsible for HBV-
related PAN usually manifest less than 12 months after
infection mainly in patients under 40 years of age.
Hepatitis is rarely diagnosed, as it remains silent before
the occurrence of PAN. Clinical manifestations are
roughly the same as those commonly observed in PAN.
The disease is acute. Seroconversion usually leads to
recovery. The major sequelae are the consequence of
vascular nephropathy and peripheral neuropathy but,
even in patients who initially develop renal insufﬁciency,
it is possible to cure PAN with little residual impairment
of renal function. Rare cases of HIV-associated PAN
(Gherardi et al., 1993) have also been reported as well as
Kawasaki disease (Johnson et al., 2003). They do not
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therapeutic approach as PAN, due to other viral infections.
Relapses
HBV-relatedPANcanbeconsideredaself-limitingdisease
which tends not to recur once remission is induced. In our
series (Guillevin et al., 1995), only 6% of the patients
relapsed. At present, it is still not possible to predict the
subgroup of patients who will relapse, or the severity of
the relapses. Due to the limited number of relapses,
maintenance treatment is not necessary.
Deaths
In all vasculitides, involvement of major organs can have
lethal complications. A few patients die early from
multivisceral involvement, often gastrointestinal, that
cannot be controlled by treatment. In such cases, the
course of the disease is generally characterized by fever,
rapid weight loss, diffuse pain and involvement of one or
several major organs involvement.
Conventional treatment with steroids and cyclo-
phosphamide jeopardize the patient’s outcome by allow-
ing the virus to persist, thereby stimulating its replication
and facilitating evolution towards chronic hepatitis and
liver cirrhosis.
Treatment of HBV-related PAN
For many years, HBV-related PAN was treated in the same
way as non-virus-related PAN and patients received
steroids, sometimes combined with cytotoxic agents,
mainly cyclophosphamide. This treatment was often
effective in short-term, but careful analysis of long-term
results showed the occurrence of relapses and compli-
cations due to virus persistence, like chronic hepatitis or
liver cirrhosis (McMahon et al., 1989).
The rationale for combining PE and antiviral treatment
was to obtain the following effects: initial corticosteroids
to rapidly control the most severe life-threatening
manifestations of PAN, which are common during the
ﬁrst weeks of the disease, and abrupt stoppage of
corticosteroids to enhance immunological clearance of
HBV-infected hepatocytes and favor HBe antigen (Ag) to
anti-HBe antibody (Ab) seroconversion. PE can almost
control the course of these PAN without the addition of
steroids or cyclophosphamide.
In 1988, in conjunction with Christian Tre ´po we
published (Tre ´po et al., 1988; Guillevin et al., 1988) the
ﬁrst results of a treatment combining antiviral treatment
and PE, after a short-term steroid regimen. Steroids and/or
immunosuppressants agents were abruptly discontinued to
remove stimulants of virus replication, which was
essential for antiviral treatment efﬁcacy. An alternative
therapy was also needed to reduce the mortality of PAN
and to improve prognosis.
When this therapeutic strategy was ﬁrst applied, the
only available antiviral agent was vidarabine. After a
3-week course of vidarabine, administered after 1 week of
steroids (1mg/kg/d) and combined with PE, a full clinical
recovery was obtained in three-quarters of the patients and
HBeAb to anti-HBeAb seroconversion was observed in
nearly half of the patients (Guillevin et al., 1993). HBsAg
to anti-HBsAb seroconversion was obtained only in 18%
of the group. This latter low seroconversion rate was
attributed to the limited efﬁcacy of vidarabine and by the
early integration of the virus genome into hepatocytes.
Other antiviral agents like interferon-alpha (IFN-a)
(Guillevin et al., 1994) or lamivudine (Guillevin et al.,
2004) should be preferred and gives better results than
vidarabine. When prescribed, IFN-a dose is comparable to
that prescribed for hepatitis B, i.e. 3 million units, 3 times
a week. When no seroconversion is observed, after 4–6
months, the dose can be increased to 6 million units,
3 times a week. Tolerance of the treatment is in fact better
than expected. The duration of the prescription does not
exceed 6 months for the majority of them.
Lamivudine is an antiviral agent speciﬁcally designed
for the treatment of HBV and HIV infections. In a small
series of patients (Guillevin et al., 2004), we perscribed
100mg of lamivudine/day, in association with PE, after a
few days steroids. Because lamivudine is eliminated by
the kidney, the dose should be lower for patients with
renal insufﬁciency and adapted to renal function. With this
treatment, 60% of the patients seroconverted to anti-HBe
and 90% recovered.
The severity of the disease in most patients requires
therapy able to control immediately the severe or life-
threatening manifestations of PAN. PE is able to rapidly
clear the immune complexes (IC) responsible for the
disease. This rapid intervention is the most appropriate to
control the disease. In our protocol, steroids are also
prescribed for a few days at the start of treatment to
control as quickly as possible the clinical manifestations,
whilewaiting for IFN-a efﬁcacy to kick in. In our opinion,
PE are not indicated because of their superiority to other
medications but because they are, in combination with
antiviral drugs, able to replace the deleterious therapies
commonly used in virus-associated vasculitides with
equivalent efﬁcacy.
The optimal schedule is as follows: 4 sessions/week for
3 weeks, then 3 sessions/week for 2 to 3 weeks, followed
by progressive lengthening of the intervals between
sessions. One plasma volume (60ml/kg) is usually
exchanged using 4% albumin replacement ﬂuid. The
high number of PE can decrease the level of clotting
factors and thereby lead to bleeding. Usually, the tolerance
of PE is excellent, although some of our patients have
experienced minor side effects.
One of the major advances obtained under the antiviral
strategy was the very rapid cure of PAN, even in its most
severe forms. It was sometimes possible to eliminate all
signs of vasculitis more quickly, with some of our patients
recovering within 3 weeks.
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plasmapheresis should be stopped to avoid the clearance
of the newly synthesized antibodies. In a few cases, the
Ab levels ﬂuctuated, sometimes being present or absent.
This Ag–Ab equilibrium can be very unstable and
treatment should be continued. In such cases, it is more
reliable to monitor virus activity by quantitative
measurements of viral DNA.
HCV CRYOGLOBULINEMIA
Clinical Characteristics of HCV-related
Cryoglobulinemia
Mixed cryoglobulinemia of type II and, more rarely,
type III are the consequence of HCV infection in
more than 80% of the patients (Agnello et al., 1992).
Cryoglobulinemia is asymptomatic in most patients but
persists for decades and the disease duration might be a
factor associated with the occurrence of clinical
symptoms. When symptoms are present, the most frequent
are purpura, peripheral neuropathy, glomerulonephritis,
leg ulcers, arthritis and sicca syndrome. Relapses are
common, and the disease is chronic even under treatment
and when virus replication has stopped.
Treatment
Only 10–20% of the patients with chronic hepatitis C
achieved a sustained virological response. Polyethylene
glycol (PEG)–IFNa-2a increased the virological response
in the recent studies where 69% of the patients had
obtained a virological response at 48 weeks and a clinical
recovery (Zeuzem et al., 2000). A combination of IFN-a
and ribavirin also increased the seroconversion rate in
hepatitis C.
No treatment is able to cure the majority of the cases of
mixed cryoglobulinemia deﬁnitively and an optimal
therapeutic strategy has not yet been clearly deﬁned.
Steroidsandimmunosuppressivedrugsarecommonlyused
to treat severe forms, but they stimulate virus replication
and can accelerate the development of chronic liver
hepatitis and cirrhosis conditions, which facilitate the
occurrenceoflivercancer.AswedidforHBV-relatedPAN,
wedevisedastrategyassociatingantiviraldrugsandPEfor
some patients (Cohen et al., 1996). For asymptomatic
patients,thereisnoargumenttotreat,andmonitoringcould
be sufﬁcient. In patients with moderate symptoms of
cryoglobulinemia vasculitis (arthralgias, purpura, sensory
peripheralneuropathy,forinstance),IFN-aincombination
with ribavirin should be tested.
Interferon-alpha and other Antiviral Agents
Treating cryoglobulinemia with IFN-a and ribavirin is
based on the regimen prescribed for HCV hepatitis. Mixed
cryoglobulinemia with clinical symptoms seems to be
a disease that becomes manifest after decades-long
chronic infection and, although there are no hard data to
support a correlation between the time of infection and
disease activity or between cryoglobulinemia level and
disease severity, we hypothesize that it is more difﬁcult to
obtain virus clearance and disease remission during the
chronic phase of cryoglobulinemia.
Clinical prospective trials using IFN-a alone (Cohen
et al., 1996), or in combination with PE and/or low-dose
steroids (Cohen et al., 1996; Rieu et al., 2002) showed that
the majority of patients improved clinically under
treatment, that the replication rate decreased in the
majority of the patients, but that a relapse occurred in
83% of the patients immediately after stopping treatment.
In the prospective trials, patients were treated for only 6
months, which is obviously insufﬁcient to obtain
satisfactory results, but that was the recommended
treatment duration for hepatitis at the time of the studies
on cryoglobulinemia.
Combining two antiviral drugs, IFN-a and ribavirin is
indicated. A correlation between virus activity and
cryoglobulinemia also needs to be conﬁrmed. Although
majority of the patients seen for symptomatic cryoglobu-
linemia have virus-positive polymerase chain reactions
(PCR), reﬂecting virus replication, a few of them remain
serologicallypositivebutbecome PCR negative,reﬂecting
past contamination.
The indications of PE in HCV-related cryoglobulinemia
are controversial. We recommend the combination of PE
and antiviral drugs based on the effectiveness observed in
many patients who failed to respond to other treatments
and in severe clinical manifestations of cryoglobulinemia:
chronic skin ulcers, glomerulonephritis, peripheral neuro-
pathy. PE should not be prescribed systematically for
every newly diagnosed case of cryoglobulinemia because
the majority of patients present no or very few symptoms,
and we do not know at present, whether or not treatment is
indeed indicated in these pauci- or asymptomatic forms.
Under PE, arteriolar ulcers regress quickly and complete
healing can be obtained in a few weeks. PE should be
tapered progressively to avoid a rebound phenomenon due
to the increased production of cryoglobulins as a
consequence of the stimulation of the B-cell clones
responsible for their production. Some of our patients
remain plasma exchange-dependent: clinical symptoms
recur or worsen while tapering or after abrupt discontinu-
ation of the sessions. New treatments could therefore be
tried and anti-CD20 Ab are a promising effective drug that
could improve the treatment of cryoglobulinemia
(Sansonno et al., 2003).
HIV-ASSOCIATED VASCULITIS
Clinical Characteristics
Vasculitides occurring during the course of HIV infection
have been reported previously (Calabrese, 1989). Most of
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nervous system. The clinical spectrum and histological
ﬁndings of HIV-related vasculitis vary widely (Gherardi
et al., 1993). Large-, medium- and small-sized arteries
can be affected. Necrotizing arteritis, non-necrotizing
arteritis, giant-cell arteritis, eosinophil arteritis and
lymphomatoid granulomatosis have been reported
(Gherardi et al., 1993). According to Calabrese, the
frequency is low (1%) (Calabrese, 1989), and most of
the reported cases were identiﬁed at autopsy.
Some cases seem to be directly caused by opportunistic
infections, such as Pneumocystis carinii, cytomegalo-
virus (CMV) or Toxoplasma gondii, non-opportunistic
infectious agents or drug-induced hypersensitivity. In a
few cases, HIV was thought to be the etiological agent
because of the in situ localization of the virus and the
absence of evidence suggesting other mechanisms.
However, the etiology remains unknown in most cases.
The pathogenesis of virus-associated vasculitis is
heterogeneous, but at least two general mechanisms
have been incriminated: ﬁrst, virus replication might
induce direct injury of the vessel wall or vascular damage
might be the result of an immune mechanism. These
mechanisms may be cellular and/or humoral and include
deposition of IC and/or their in situ formation.
Treatment
The treatment of HIV-related vasculitis has the double
objective to cure the vasculitis and to control the HIV
infection. For this reason it seems of major importance not
to prescribe steroids and cytotoxic agents. The ﬁrst
objective is to suppress HIV replication, which is more
easily obtained with the combination of 2, 3 or 4 antiviral
agents. Nucleotidic, non-nucleotidic inhibitors, and
protease inhibitors are the most frequently used families
of drugs. The treatment of vasculitis is not easy to
establish, because the pathogenetic mechanisms of
the disease are not completely understood. Based on the
presence of CIC, we have proposed (Gisselbrecht et al.,
1997), as for other virus-associated vasculitides, to treat
the patients with PE, using the same scheme as that to
HBV-related PAN. In our clinical experience, this
association was successful and the ﬁrst 8 patients we
treated improved and remissions were obtained. In some
patients who presented with co-infections, i.e. HCV and
HIV or HBV and HIV, this strategy was also effective.
Some patients with cryoglobulinemia responded very
quickly to the regimen.
HIV-related vasculitides appear to be a one-shot disease
and do not recur. A short treatment, 1 to 3 months, is
usually sufﬁcient to cure the disease.
MISCELLANEOUS
Other viruses have also be described in association
with vasculitis: parvovirus, Epstein Barr virus etc. It is
sometimes difﬁcult to establish a close relationship
between viral infection and vasculitis. Recently, we
successfully treated a patient who had developed PAN
after parvovirus infection with intravenous immuno-
globulins alone; the patient recovered quickly (Viguier
et al., 2001).
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